newsfilter
← Latest News
GlobeNewswire·

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA

KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and devel